08 February 2021>: Clinical Research
Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models
Ming Chen 1BCE* , Ting Ma 1CDE* , Jun Li 1AEG* , Hai-Jun Zhang 2D , Qiang Li 3F , Jia-Jia Wang 1F , Tian Sang 1B , Chun-Li Cao 1D , Xin-Wu Cui 4AEF*DOI: 10.12659/MSM.929913
Med Sci Monit 2021; 27:e929913
Table 2 Verifying the diagnostic value of clinical parameters by using univariate and multivariate logistic regression analyses in predicting BPH vs PCa.
Parameters | Univariable analysis | Multivariable analysis | |||||
---|---|---|---|---|---|---|---|
OR (95% CI) | Standard error | P | Coefficient | Standard error | OR (95% CI) | P | |
Constant | – | – | – | 1.95 | 0.71 | – | |
Age | 1.03 (0.99, 1.07) | 0.02 | 0.15 | – | – | – | – |
tPSA | 1.18 (0.96, 1.47) | 0.11 | 0.12 | – | – | – | – |
f/t PSA | 0.01 (0.00, 0.06) | 1.64 | −6.61 | 1.86 | 0.01 (0.00, 0.05) | ||
PSADa | 2.52 (1.53, 4.15) | 0.25 | 0.88 | 0.28 | 2.41 (1.40, 4.16) | ||
DRE | 3.81 (0.95, 15.24) | 0.71 | 0.06 | – | – | – | – |
TRUS (1)b | 1.32 (0.68, 2.56) | 0.34 | 0.42 | – | – | – | – |
TRUS (2)c | 1.15 (0.51, 2.60) | 0.42 | 0.74 | – | – | – | – |
mpMRI (1)d | 3.08 (1.34, 7.06) | 0.42 | 1.04 | 0.46 | 2.83 (1.14, 6.99) | 0.02 | |
mpMRI (2)e | 5.24 (2.47, 11.10) | 0.38 | 1.41 | 0.42 | 4.11 (1.81, 9.33) | ||
PCa – prostate cancer; PSA – prostate-specific antigen; OR – odds ratio; CI – confidence interval; tPSA – total PSA; f/t PSA – free/total PSA; PSAD – PSA density; DRE – digital rectal examination; TRUS – transrectal ultrasound; mpMRI – multiparametric magnetic resonance imaging. ‘−’ – Not applicable. a This parameter has been log-transformed; b Negative vs Equivocal in TRUS; c Equivocal vs Suspicious in TRUS; d Negative vs Equivocal in mpMRI; e Equivocal vs Suspicious in mpMRI. |